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Muscle atrophy is the result of two opposing conditions that can be found in pathological or diseased
muscles: an imbalance in protein synthesis and degradation mechanisms. Thus, we investigated whether
exogenous melatonin could regulate muscle components in stroke-induced muscle atrophy in rats.
Comparing muscle phenotypes, we found that long-term melatonin administration could influence muscle
mass. Muscle atrophy-related genes, including muscle atrophy F-box (MAFbx) and muscle ring finger 1
(MuRF1) were significantly down-regulated in melatonin-administered rats in the gastrocnemius. However,
only MAFbx at the mRNA level was attenuated in the soleus of melatonin-administered rats. Insulin-like
growth factor-1 receptor (IGF-1R) was significantly over-expressed in melatonin-administered rats in both
the gastrocnemius and soleus muscles. Comparing myosin heavy chain (MHC) components, in the
gastrocnemius, expression of both slow- and fast-type isoforms were significantly enhanced in melatonin-
administered rats. These results suggest that long-term exogenous melatonin administration may have a
prophylactic effect on muscle atrophy through the MuRF1/MAFbx signaling pathway, as well as a potential
therapeutic effect on muscle atrophy through the IGF-1-mediated hypertrophic signaling pathway in a
stroke animal model.
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Skeletal muscle atrophy is a change that can occurs in
the muscles of adult animals as a result of several causes,
such as disuse (e.g., immobilization, denervation, space
flight), starvation, and some diseases [1-5]. Additionally,
muscle atrophy can take place secondary to some
devastating injuries or common health problems, such as
injuries of the central nervous system (e.g., stroke, spinal
cord injury), aging, and various systemic diseases [1].
Muscle atrophy is the result of an imbalance between
two opposing conditions that can occur in pathological
or diseased muscles: an imbalance in protein synthesis
and degradation mechanisms [6-9]. Atrophy is characterized
by wasting or loss of muscle mass and usually involves
a decrease in the size or cross-sectional area (CSA) of
individual myofibers [8,9]. Previous studies demonstrated
that the slow-twitch fibers of the extensor muscles in
young rats during space flight (SF)-induced atrophy
were particularly sensitive to atrophy [1,3]. Paretic
muscle atrophy, associated with acute brain injury, is
characterized by the appearance of variability in fiber
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diameter, nuclear internalization, and perifascicular fatty
infiltration [11].
Inflammation is a fundamental pathogenic mechanism
in stroke. Elevated inflammatory markers predict risk for
incident and recurrent stroke [10]. Tumor necrosis
factor-α (TNF-α), an inflammatory cytokine, is expressed
at negligible levels in normal muscle but is elevated
under selected metabolic conditions characterized by
muscle wasting and insulin resistance [9,10]. Thus,
previous studies have reported that the expression of
TNF-α mRNA is increased in the skeletal muscle of
stroke patients [7,10,12]. TNF-α may contribute to
atrophy through a number of mechanisms, including
inhibition of protein synthesis, transcriptional regulation
of myofiber gene expression, and accelerated protein
breakdown through activation of ubiquitin proteases,
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB), and apoptotic cell death [10,13]. TNF-α
appears to preferentially down-regulate MHC type I
protein synthesis and enhance its degradation. However,
it elevated MHC type II in paretic muscles [10,11].
Numerous studies have demonstrated that over-
expression of NF-κB in disuse conditions activates the
machinery of MAFbx/MuRF1 signaling [6,10]. These
genes are expressed only in skeletal muscle and
myocardium and have been found to be expressed at
elevated levels under all conditions involving atrophy,
including denervation [10,13,14]. Over-expression of
MuRF1 reduces the size of cultured muscle cells, and
MAFbx targets the myosin heavy chain for degradation
[9]. A protein imbalance in skeletal muscle activates the
PI3K/Akt/mTOR signaling pathway. Phosphatidylinositol
3-kinases (PI3K) activate Akt, leading to reduced
tuberous sclerosis complex (TSC1/2) and forkhead box
(FOXO) protein. The TSC1/2 protein inhibits mammalian
target of rapamycin (mTOR) signaling, and once TSC1/
2 is reduced, mTOR increases, increasing expression of
p70S6K in ribosomes [8,9].
IGF-1 is a major upstream molecule in muscle
hypertrophy. Thus, the recovery machinery is activated,
followed by expression of IGF-1 [5,6,14]. Other studies
reported that IGF-1 induced activation of the PI3K/Akt/
mTOR signal pathway, increasing the proliferation of
satellite cells [14-16].
Administration of IGF-1 is mitogenic for myoblasts,
increases muscle protein content, and reduces protein
degradation [14]. More importantly, over-expression of
IGF-1 has been associated with the proliferation of
satellite cells [14,16] when injected into an acute
contusion, laceration, or strained muscle, increasing
regeneration [14,16,17]. IGF-1 not only inhibits atrophy
signaling but also activates the PI3K/Akt/mTOR signaling
pathway [14,17,18].
Melatonin, the major secretory product of the pineal
gland, is known to interact with the neuroendocrine axis
and circadian rhythms [19-23]. In a previous study, we
demonstrated that exogenous and endogenous melatonin
has a prophylactic effect on muscle atrophy in the
hindlimb in spinal cord-injured rats [20]. In vivo studies
have shown that melatonin treatment increases the
expression of IGF-1 in a castration animal model [21].
Thus, in this study, we investigated whether exogenous
melatonin could regulate muscle components in stroke-
induced muscle atrophy in rats.
Materials and Methods
Experimental animals and maintenance
All animal procedures were approved by the Ethics
Committee for Animal Care and Use at Inje University
(Approval No. 2010-21). The rats were randomly
divided the control (Con), and MCAo groups (Veh:
MCAo+vehicle, MT7: MCAo+melatonin injection at
7:00, MT19: MCAo+melatonin injection at 19:00, and
MT7,19: MCAo+melatonin injection at 7:00 and
19:00). Focal cerebral ischemia was induced by a
modified intraluminal occlusion method, as described
previously [22,23]. Briefly, the junction of right common
carotid artery was exposed under operating microscope.
A 4-0 Nylon thread, with its tip blunted by heating over
flame, was inserted 18.5±1.0 mm from external into the
internal carotid artery until the tip occluded the origin of
the MCA. After closure of the operative sites, the
animals were temporarily transferred to a cage with a
heating lamp. The thread was gently removed at 60 min
of MCA occlusion. Melatonin (Sigma-Aldrich, St Louis,
MO, USA) was dissolved in a mixture of EtOH and
0.9% physiological saline (final concentration, 5%).
Fresh melatonin solution was prepared in a dark room
with switch on the red lamp. Animals were injected
subcutaneously melatonin (10 mg/kg) or Veh (EtOH-
0.9% physiological saline) at 7:00 and 19:00 from 24 hr
after MCAo. Neurological deficiency tests were conducted
as described previously [22].Improvement of muscle atrophy by melatonin 49
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Gene analysis and histological analysis
The animals were sacrificed after anesthetized by
cocktail of zoletil (40 mg/kg) with xylazine (10 mg/kg).
The fresh skeletal muscle tissues were homogenized
with 1ml of Tri-reagent (Sigma-Aldrich, St. Louis, MO,
USA) to prepare a total RNA samples. The RNA was
reverse transcribed with oligo d(T) 12~18 using reverse
transcriptase #18064-014 (Invitrogen, Carlsbad, CA,
USA) and this reaction mixture served as a template for
polymerase chain reaction (PCR). To identify gene
transcription, a reaction mixture (50 µL) for PCR was
made up of 2.0 µL of cDNA synthesis mixture, 40 nM
dNTPs, 10 pM of sense and antisense primer, and 1.25
U of GoTaq
® DNA polymerase (Promega, Medison, WI,
USA). PCR were performed with denaturation at 95
oC
for 30 sec, annealing at 60
oC for 1 min, and extension at
72
oC for 1min in each cycle, followed by a final 10 min
extension at 72
oC using Px2 Thermal cycler HBPX2220
(Thermo electron corporation, Waltham, MA, USA).
Primer sets are listed in Table 1. The histological study
also used previously described methods for hematoxylin
and eosin (H&E) staining [22].
Statistical analysis
Data were collected from repeated experiments and
are presented as mean±SD. A one-way ANOVA was
used for statistical analysis. Differences were deemed
statistically significant when P<0.05. Analysis were
performed using the SPSS software (ver. 19.0, IBM,
Chicago, IL, USA).
Results
Phenotype of hindlimb muscles
Based on previous results, we assessed melatonin
treatment and changes in hindlimb muscles. The MT19
group showed significantly attenuated muscle mass loss
in both the right and left hindlimbs (P<0.01; Figure 1A).
Similar results were observed in the soleus muscles
(Figure 1B). However, MT7,19 rats showed no difference
in the gastrocnemius muscle compared with the Con,
indicating recovery of muscle mass following melatonin
treatment (Figure 1A). From the histological study, long-
term melatonin administration may enhance the volume
of muscle fibers. Interestingly, we also found a mild
accumulation of fat between muscle fibers in the soleus
of MT19 rats (Figure 2).
Regulation of the mechanism of muscle atrophy
The regulation of muscle atrophy is important for
rehabilitation therapeutic approaches in recovery-stage
patients after a stroke. Briefly, the physiological condition
of muscle tissues has to be appropriate for functional
movement. Thus, we compared to atrophy-related gene
expression in innervated hindlimb muscles following the
time of melatonin administration in focal cerebral
ischemic rats. In typical intermediate-type muscles, such
as the gastrocnemius, the MAFbx and MuRF1 genes are
significantly suppressed following long-term melatonin
administration. In particular, MT7,19 rats showed a
strong protective effect against stroke-induced muscle
Table 1. Oligonucleotide primers used for RT-PCR
Gene Primer sequence (5' to 3') Product length (bp) GenBank accession No.
MAFbx  F: GCAAAACATAAGACTCATACG
 R: GTAGAGTGGTCTCCATTCG 83 NM_133521
MuRF1  F: AGGTGAAGGAGGAACTGAG
 R: AACTGCTCTCGGTACTGG 86 NM_080903
MHC-Iβ  F: CAGAGGAAGACAGGAAGAACCTAC
 R: GGGCTTCACAGGCATCCTTAG 288 K01463
MHC-IIa  F: CCTCTTACTTCCCAGCTGCACCTTCT
 R: CTTTCCCTGCGTCTTTGCTCCTGAAT 239 DQ872905
MHC-IIb  F: ACGGTCGAAGTTGCATCCCTAAAG
 R: CACCTGGTCTTGGCTGTCAC 263 DQ872906
MHC-IIx  F: AGCCTGCCTCCTTCTTCATCTGG
 R: CAGGTTGCTTTCACATAGGACTC 229 DQ872907
IGF-1R  F: TCCCAAGCTGTGTGTCTCTG
 R: GTGCCACGTTATGATGATGC 178 NM_052807
GAPDH  F: GTATGACTCCACTCACGGCAAA
 R: GGTCTCGCCTCCTGGAAGATG 100 BC09403750 Seunghoon Lee et al.
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atrophy (P<0.01; Figure 3A). At the same time,
melatonin turned on the hypertrophic signaling pathway
through IGF-1R expression in the MT7,19 group
(P<0.01, P<0.01; Figure 3A).
In a slow-twitch muscle, such as the soleus, MAFbx
gene expression was significantly down-regulated by
twice daily melatonin administration, at 7:00 and 19:00
(P<0.01, P<0.01; Figure 3B). However, MuRF1 was
unaltered. IGF-1R gene expression was clearly enhanced
in the soleus of MT7,19 rats (P<0.01, P<0.01; Figure
3B).
Figure 1. Changes in muscle mass following melatonin administration for 8 weeks after MCAo. (A) Gastrocnemius, (B) Soleus.
Right means to sound side hindlimb. Left means to affected side hindlimb. Rt: right hindlimb; Lt: left hindlimb; Con: control; Veh:
MCAo+vehicle; MT7: MCAo+melatonin injection at 7:00; MT19: MCAo+melatonin injection at 19:00; MT7,19: MCAo+melatonin
injection at 7:00 and 19:00. **P<0.01 vs. Con.
Figure 2. Morphology of hindlimb muscles following melatonin administration for 8 weeks after MCAo. Veh: MCAo+vehicle; MT7:
MCAo+melatonin injection at 7:00; MT19: MCAo+ melatonin injection at 19:00; MT7,19: MCAo+melatonin injection at 7:00 and
19:00. Scale bar=100 µm.Improvement of muscle atrophy by melatonin 51
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Alteration of myosin heavy chain (MHC) components
We measured whether exogenous melatonin caused
changes in MHC components during recovery after
stroke. In the gastrocnemius, all MHC components
showed similar expression. After 8 weeks of treatment,
Veh rat showed greater expression of MHC-IIb in fast-
twitch type muscles compared with that in Con (P<0.01;
Figure 4A). However, MT7 and MT7,19 rats showed
up-regulated expression of all MHC components.
Especially in the MT7,19 rat, MHC components were
significantly enhanced in both slow- and fast-twitch
muscle types after 8 weeks (P<0.01). MT7 rats showed
a similar effect in the gastrocnemius (Figure 4A).
The results in the soleus were interesting. The soleus
is a typical slow-twitch muscle in the hindlimb. We
observed spontaneous restoration of MHC-Iβ components
in stroke-induced muscle atrophy (Figure 4B), indicating
that exogenous melatonin had a therapeutic effect
against stroke-induced muscle atrophy.
Discussion
In previous studies, we confirmed that melatonin
could prevent oxidation-induced cell death as well as
improve neurological function in focal cerebral ischemic
rats [22,23]. We suggested that melatonin might be
useful as a therapeutic agent for focal cerebral ischemia.
However, stroke leads to atrophy of ipsilateral brain-
innervated skeletal muscles. Thus, we analyzed atrophy-
related gene expression and changes in MHC isoforms.
Skeletal muscle function is fundamental for functional
restoration in stroke patients [7,13]. Thus, clinical trials
have examined the efficacy of treatments for the
rehabilitation of neurological disorder patients. Skeletal
muscle characterized the change of muscle type under
physiological condition, and the existence of intrinsic
differences between muscles that limit the range of
possible adaptations by external environments [24].
Therefore, we examined whether exogenous melatonin
had a beneficial effect in stroke-induced muscle atrophy
in the gastrocnemius and soleus muscles. A recent study
reported that TNF-α was elevated in paretic muscles in
stroke patients [10]. TNF-α contributes to atrophy through
a number of mechanisms, including inhibition of protein
synthesis, transcriptional regulation of myofiber gene
expression, and accelerated protein breakdown through
activation of ubiquitin proteases and NF-κB. TNF-α
appears to preferentially down-regulate MHC-type I
Figure 3. Changes of muscle atrophy- and hypertrophy-related gene expression on stroke-induced muscle atrophy in the
gastrocnemius (A) and soleus (B). MT7,19 rats showed inhibition of both MAFbx and MuRF1 mRNA expression and an increase in
hypertrophic upstream molecules, such as IGF-1R expression. Con: control; Veh: MCAo+vehicle; MT7: MCAo+ melatonin injection
at 7:00; MT19: MCAo+melatonin injection at 19:00; MT7,19: MCAo+melatonin injection at 7:00 and 19:00. (A) **P<0.01 vs. Con;
##P<0.01 vs. Veh. (B) *P<0.05, **P<0.01 vs. Con; 
#P<0.05, 
##P<0.01 vs. Veh.52 Seunghoon Lee et al.
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protein synthesis and enhance its degradation. However,
it elevated MHC-type II in the paretic muscle [9,10,14].
Previous studies demonstrated that the MuRF1 and
MAFbx genes are major players in the muscle atrophy
signaling pathway. Over-expression of MuRF1 reduces
the size of cultured muscle cells, and MAFbx targets the
myosin heavy chain for degradation [8,9]. Lin et al [25]
reported that melatonin has not only beneficial effects to
attenuate systemic inflammatory cytokines, such as
TNF-α, IL-Iβ, and IL-6 but also promotes an anti-
inflammatory cytokine, including IL-10 on heatstroke-
induced multiple organ dysfunction syndrome. We
found that middle cerebral artery occlusion (MCAo) rats
showed slightly enhanced expression of MAFbx/
MuRF1 mRNA levels, and exogenous melatonin had a
prophylactic and therapeutic effect during stroke-induced
muscle atrophy. Exogenous melatonin has differential
effects, depending on administration time. This may be
related to the plasma concentration of melatonin. In a
previous study, we confirmed that a controlled photoperiod
could change plasma levels of melatonin [26]. Moreover,
therapeutic effect of melatonin could modulate via both
photoperiod control and exogenous melatonin administration
on reconstruction of neural network after spinal cord
injury in rats [20]. In clinical trials, likewise, melatonin
administration (10 mg/day) induces reduction of
progression of non-alcoholic fatty liver disease through
improves plasma liver enzymes [27]. Thus, we examined
whether melatonin levels in plasma affected physiological
conditions. Our results suggest that melatonin might
attenuate stroke-induced muscle atrophy by down-
regulating the MAFbx/MuRF1 signaling pathway.
Additionally, exogenous melatonin may be a possible
candidate for hormonal therapy in stroke-induced muscle
atrophy. Moreover, melatonin administration time might
be an important factor for physiological effect of
melatonin in vivo.
Protein imbalance in skeletal muscle activates the
PI3K/Akt/mTOR signaling pathway [1,4,8]. When PI3K
is activated by IGF-1, it reduces the levels of TSC1/2
and FOXO proteins. TSC1/2 inhibits the mTOR signaling
pathway. Consequently, when TSC1/2 is decreased,
mTOR increases protein synthesis in ribosomes. IGF-1
is an upstream molecule in the PI3K/Akt/mTOR signaling
pathway. Another study reported that exogenous IGF-1
increased the proliferation of satellite cells in skeletal
muscle [13-15]. Administration of IGF-1 increased
muscle protein content and down-regulated protein
Figure 4. Changes of MHC components on stroke-induced muscle atrophy in the gastrocnemius (A) and soleus (B). MT7 and
MT7,19 rats showed increases in both slow- and fast-type MHC isoforms. Con: control; Veh: MCAo+vehicle; MT7: MCAo
+melatonin injection at 7:00; MT19: MCAo+melatonin injection at 19:00; MT7,19: MCAo+melatonin injection at 7:00 and 19:00. (A)
*P<0.05, **P<0.01 vs. Con; 
#P<0.05, 
##P<0.01 vs. Veh. (B) *P<0.05, **P<0.01 vs. Con; 
#P<0.05, 
##P<0.01 vs. Veh.Improvement of muscle atrophy by melatonin 53
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breakdown [14,21]. We demonstrated that exogenous
melatonin could activate the transcription of IGF-1
mRNA. This means that IGF-1R is turned on in
downstream signaling pathways, such as the PI3K/Akt/
mTOR signaling pathway.
Here, we suggest that the therapeutic effect of
melatonin might have different physiological effects
following the time of melatonin administration. At this
point, we considered the re-arrangement of MHC
components in muscle types.
We next analyzed the expression of MHC mRNA
levels in the gastrocnemius and soleus. The gastrocnemius
muscle is a well-known intermediate-type muscle, and
its properties can be affected by changes in the extrinsic
environment [13]. However, there was not altered the
muscle phenotype in gastrocnemius after focal cerebral
ischemia. We found similar results with MAFbx and
MuRF1 gene expression. MAFbx was not significantly
altered in the gastrocnemius. In contrast, MuRF1 was
significantly activated at the mRNA level in the
gastrocnemius of Veh rats, suggesting that stroke-induced
muscle atrophy involves non-specific protein degradation
in the gastrocnemius. Additionally, all of MHC isoforms
were significantly observed an increment of mRNA
level in the MT7 and MT7,19 rats. The soleus is a typical
slow-twitch muscle. The MAFbx mRNA level was
slightly increased in the soleus in the Veh rats and
significantly down-regulated in MT7,19 rats (P<0.01),
indicating that the soleus showed reduction in muscle
fiber size after stroke, and protein degradation could be
reduced by exogenous melatonin. Comparing the MHC
components in the gastrocnemius, MT7 and MT7,19 rats
showed significantly increased MHC-Iβ ( P<0.05),
MHC-IIa (P<0.01), and IIx (P<0.01). In the soleus, all
MHC components were significantly up-regulated by
melatonin administration at 7:00 (MHC-IIb: P<0.05;
MHC-Iβ, -IIa, IIx: P<0.01). The gastrocnemius and
soleus muscles showed only loss of the MHC-IIx
isoform; the other isoforms of MHC were augmented by
exogenous melatonin. This indicates that in stroke-
induced atrophy, a slow-twitch muscle might transform
to a fast-twitch muscle. On the other hands, the soleus
might not be affected by stroke. We also found that
melatonin could induce protein synthesis. Accordingly,
stroke-induce muscle atrophy leads to break down the
MHC of fast type in hindlimb muscles, and is turned on
the recovery machinery for protein synthesis followed
by melatonin administrating time-point. The limitation
of this study, further investigation of the appropriate
mechanism related with the restoration of neurological
function and recovery of muscle atrophy following
melatonin administration is required. In here, we suggest
that melatonin might have physiological effects which
might be diverse following administrating time-points.
In conclusion, these results suggest that long-term
exogenous melatonin treatment might have a prophylactic
effect against muscle atrophy through the MuRF1/
MAFbx signaling pathway, as well as a therapeutic effect
in muscle atrophy via the IGF-1-mediated hypertrophic
signaling pathway in a stroke animal model.
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